Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to assess the safety and efficacy of 52 weeks of open-label
treatment with the fixed dose combination of telmisartan 80 mg plus HCTZ 12.5 mg and
telmisartan 40 mg plus HCTZ 12.5 mg in patients with essential hypertension.